---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-021496"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2026-05-15T11:50:30+00:00"
generated_at: "2026-05-15T11:55:07.290659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galectin Q1 net loss narrows to $5.1M; belapectin data at EASL, FDA meeting ahead

## Summary
- Net loss of $5.1M ($0.08 per share) vs $9.6M ($0.15) in Q1 2025; R&D expense fell to $2.2M from $6.5M.
- Cash $14.1M as of Mar 31, plus $10M credit line from chairman; company expects to fund ops through May 2027.
- Belapectin 2 mg/kg showed statistically significant liver stiffness reductions (FibroScan) at Weeks 26, 52, 78 in NAVIGATE trial.
- Oral/poster presentations at EASL Congress May 28-30; Type-C FDA meeting scheduled for Q2 2026.
- Board appointed Dr. Henry Brem in Jan 2026; KOL event on MASH cirrhosis held in March 2026.

## SEC filing metadata
- accession: 0001140361-26-021496
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2026-05-15T11:50:30+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/0001140361-26-021496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/ef20073003_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-021496
- JSON: https://secwatch.observer/filing/0001140361-26-021496.json
- Plain text: https://secwatch.observer/filing/0001140361-26-021496.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported three months ended March 31, 2026 results: net income $5.1 million, or ($0.08) per share, EPS ($0.08) per share.
  - Period: three months ended March 31, 2026
  - Net income: $5.1 million, or ($0.08) per share
  - EPS: ($0.08) per share
  - Result: reported results
  source text: For the quarter ended quarter ended March 31, 2026, the Company reported a net loss applicable to common stockholders of $5.1 million, or ($0.08) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/0001140361-26-021496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.